Hereditary breast and ovarian cancer testing: Integration and outcomes within community oncology practices

Community Oncology

Volumn 7, Issue 2, 2010, Pages 75-81

  Eisenbraun, Ann ^a   Wenstrup, Richard ^a   Hellerstedt, Beth ^b   Patton, Jeff ^c   Reid, Julia ^a   Sailer, Lisa ^b   Copeland, Karen ^a   Brunger, Jeanne ^a   Hamilton, Stephanie ^a   Frye, Cynthia ^a   Sandbach, John ^b  

^a Myriad Genetic Laboratories   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Tennessee Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER TEST; CONTROLLED STUDY; ETHNICITY; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; OVARY CANCER; PREVALENCE; QUESTIONNAIRE; RISK REDUCTION; SALPINGOOOPHORECTOMY;

EID: 77649209488     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70558-7     Document Type: Article

References (28)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
3. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
4. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302 :643-646.
5. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710.
6. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816.
7. Parlanti AA, Burbidge LA, Shappell HL, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with bilateral invasive breast cancer. Paper presented at: 26th Annual San Antonio Breast Cancer Symposium; December 3-6, 2003; San Antonio, TX.
8. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
9. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
10. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
11. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
12. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Available at: www.cancer.org/docroot/STT/stt-0.asp. Accessed February 4, 2010.
13. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
14. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:855-861.
15. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology-V.1.2009. Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2009. Available at: http://www.nccn.org. Accessed February 4, 2010.
16. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006;118:2281-2284.
17. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
18. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-1062.
19. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
20. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
21. Hendrickson BC, Judkins T, Ward BD, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer 2005;43:309-313.
22. Beaudet AL, Tsui LC. A suggested nomenclature for designating mutations. Hum Mutat 1993;2:245-248.
23. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676.
24. Myriad Genetics Laboratories Inc. The 2008 BRCA1/2 Gene Mutation Prevalence Tables. 2008. Available at: www.myriadtests. com/pdfs/BRCA-Mutation- Prevalence-Percentages.pdf. Accessed February 4, 2010.
25. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
26. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009;115:2222-2233.
27. Dominguez FJ, Jones JL, Zabicki K, et al. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 2005;104:1849-1853.
28. Hughes KS, Roche C, Campbell CT, et al. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J 2003;9:19-25.